Mitch Steves is an Analyst at RBC Capital Markets primarily focused on networking equipment and semiconductor companies. In 2016 and 2017, he was noted as a “Rising Star of Wall Street Research” according to Institutional Investor magazine in three categories: Telecom & Networking Equipment, Semiconductors and IT Hardware/EMS. He started at RBC in 2011 and launched coverage in 2015. Earlier, he held positions at Gleacher and Company covering hardware and networking equipment and worked as an investment banker at Cowen and Company. He holds an economics degree from the University of California Berkeley.
Charles Anderson serves as Vice President, Senior Research Analyst within the Equity Capital Markets division at Dougherty & Company LLC. He covers the mobile computing industry with a focus on supply chain, components and software applications. He has been with Dougherty & Company since 2007 and his research experience includes location-based services and intelligence, reconnaissance and surveillance — ISR — companies. Prior to joining Dougherty & Company, he was a business journalist covering the technology, telecommunication and utilities sectors. Mr. Anderson earned a bachelor’s of journalism degree from the University of Missouri – Columbia.
Ronnie Moas is the Founder and Director of Research at Standpoint Research, Inc. He started Standpoint Research in 2004. He began his career on Wall Street as an analyst and market strategist at Herzog Heine Geduld. Earlier, he worked at Shuki Weiss International Concert Productions where a few of his production credits included the Haifa Seaport Blues Festival, Bob Dylan, Radiohead, Buddy Guy and Suede. Mr. Moas was a sergeant in the Israeli army from 1987 until 1990.
Manisha Samy is an Analyst at ARK Investment Management LLC. Ms. Samy joined ARK as a thematic analyst on the Genomic Revolution team in February 2016. Her focus is on gene editing, gene therapy, instrumentation, targeted therapeutics, agricultural biology, diagnostics and stem cells. Prior to ARK, Ms. Samy worked as a management consultant for Kepler Cannon. Before that, she gained experience as a business solution analyst at Attensity America. Ms. Samy graduated from Stanford with a Bachelor of Science in science, technology and society: life sciences and biotechnology. She has spent eight years in Stanford’s research lab studying stem cells in acute myeloid leukemia.
Jesse Pytlak, CFA, is an Analyst in the Institutional Equity Research department of Cormark Securities Inc. and covers the cannabis industry. He joined Cormark in 2013. Previously, Mr. Pytlak worked at Ewing Morris & Co. Investment Partners and State Street. He received his Bachelor of Commerce with honors from McMaster University in 2007 and his Master of Finance from Queen’s University School of Business in 2013.
David Kideckel is a Managing Director and Senior Equity Research Analyst at AltaCorp Capital Inc., heading the firm’s life sciences research franchise. Prior to joining AltaCorp Capital, Dr. Kideckel was at another leading independent investment dealer, in his role as Director of Healthcare & Biotechnology, Institutional Equity Research. Dr. Kideckel is a seasoned industry executive, having spent nearly 15 years in international pharmaceutical, biotechnology and medical device companies where he held executive roles in sales, marketing, medical affairs and international business development. Dr. Kideckel holds a Ph.D. and MBA from the University of Toronto’s Institute of Medical Science and Rotman School of Management, respectively. He is a university Gold Medalist and a recipient of the Canadian Institutes of Health Research Science to Business Award.
Austin Moldow is a Vice President and Equity Research Analyst at Canaccord Genuity LLC. He covers emerging media and technology companies, wherein he leverages six years of research experience covering internet and technology stocks to uncover disruptive companies and opportunities related to entertainment content. He received a B.A. in economics from Rutgers University.
James Lee is a Managing Director at Mizuho Securities USA LLC and covers U.S. and China internet with a focus on the convergence of online and mobile, the migration of advertising to digital and the emergence of mobile messaging and voice search. He has pioneered a product-case-studies approach in assessing the fundamentals of internet companies and internet trends globally, working with leading industry practitioners to extrapolate leading indicators for investment analysis. Mr. Lee’s industry calls span across key topics such as advertising, commerce, mobile messaging and Asia versus U.S. business models. He has strong relationships with companies/industry contacts in Asia and periodically hosts events between management teams and investors in the U.S./Asia. Mr. Lee has received recognitions from various surveys, including Institutional Investor, StarMine, Forbes and South Morning Post. Prior to Mizuho, he was affiliated with CLSA, Fidelity Investments, UBS, Oppenheimer and WR Hambrecht.
Yun Zhong is an Equity Research Analyst and Director of biotechnology research at Janney Montgomery Scott LLC. Dr. Zhong joined Janney in 2017 with over seven years of experience as an associate covering the biotechnology industry. He has experience in several therapeutic areas, including gene therapy, rare diseases, central nervous system disorders, infectious diseases, hepatobiliary disorders, among others. Earlier, Dr. Zhong spent three years at SunTrust Robinson Humphrey. Between 2011 and 2014, he worked as a biotechnology equity research associate at Cowen and Company. Dr. Zhong received his Ph.D. in neuroscience and molecular biology from Rockefeller University, and M.S. and B.S. degrees in biophysical engineering from Osaka University in Japan. He also was a postdoctoral fellow in neurology at New York’s Mount Sinai School of Medicine.
Raju Prasad is an Analyst focused on therapeutics at William Blair & Company, L.L.C. He joined the firm in March 2014. Dr. Prasad previously worked as a research associate at the University of North Carolina’s Gillings School of Global Public Health and as an independent consultant with the U.S. Environmental Protection Agency. Dr. Prasad has a degree in cell biology and neuroscience from Rutgers University, an M.S. degree in exercise physiology from the University of Delaware and a Ph.D. in environmental sciences and engineering from the University of North Carolina at Chapel Hill with a focus in genetic toxicology and mutagenesis.
